Patient Specific Cellular Models for Personalized Medicine

This direction is merged into another direction: patient-specific cellular modeling. Its last version stays readable and citable here.

Version 1 of 119 papers22 conceptsfrozen 2026-10-04

The central challenge in modern drug development is the "translational gap": the high failure rate of therapies that appear promising in animal models but fail in human clinical trials. This failure often stems from the fact that standard laboratory models—whether mice or immortalized cell lines—cannot replicate the complex, polygenic genetic background of an individual human patient.

To bridge this gap, researchers are increasingly using patient-specific induced pluripotent stem cells (iPSCs) to create "disease-in-a-dish" models. By reprogramming a patient's own skin or blood cells back into a stem-cell state and then differentiating them into specific tissues (like neurons or heart cells), scientists can study a disease within the exact genetic context of the person suffering from it.

The Living Biopsy

For many conditions, particularly those affecting the brain or heart, obtaining live tissue samples for study is impossible. As Emily G. Baxi and colleagues describe in the Answer ALS initiative, iPSC-derived neurons serve as a "functional biopsy-equivalent." This approach allows researchers to observe how a patient's specific genetic mutations—such as those in the POLR3A gene causing leukodystrophy studied by Dan‐dan Ruan (Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation)—manifest in the very cell types the disease targets.

Preserving the Genetic Landscape

Unlike traditional models that focus on a single "knockout" gene, patient-derived models preserve the entire genetic and epigenetic landscape of the donor. This is crucial for understanding complex, polygenic disorders. For example:

Linking the Dish to the Clinic

A critical validation of this technology is whether these lab-grown cells actually reflect the patient's clinical reality. Helen Rowland and her team found that the physical shape (morphology) of iPSC-derived astrocytes correlates with the donor's actual clinical inflammatory markers and genetic risk (iPSC-Astrocyte morphology reflects patient clinical markers). This "cellular memory" suggests that in vitro models are not just generic cells, but high-fidelity proxies of the patient's state.

This connection enables "deep phenotyping," where clinical data is integrated with molecular data from iPSCs. Lenka Krčmář highlights this in the Munich Clinical Deep Phenotyping study, which uses stem cell biobanking to identify biological signatures of treatment resistance in mental illness.

Precision Drug Screening and Therapy

The ultimate goal of these models is to move from reactive to proactive medicine, as discussed in the 7th Santorini Conference led by Bws Sobral. This takes several forms:

  1. Safety Screening: Mikayla N Richter used human stem cell-derived enteric neurons to identify drugs that protect against chemotherapy-induced toxicity (Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicity).
  2. Efficacy Testing: Rachelle Balez used iPSC models of Alzheimer’s to validate the neuroprotective effects of apigenin in a human-specific context (Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease).
  3. Ex Vivo Gene Therapy: Antonio Filareto demonstrated that iPSCs can be genetically corrected in the lab and then used to restore function in models of muscular dystrophy (An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells).

By moving beyond the limitations of animal biology and general-purpose cell lines, patient-specific models provide a platform where the unique genetic identity of the individual becomes the foundation for their own treatment.

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_patient_specific_cellular_models_for_per_42ac6964,
  title = {Patient Specific Cellular Models for Personalized Medicine},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/patient-specific-cellular-models-for-personalized-medicine/rdr_42ac6964bebe4580b691976098538141},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_patient_specific_cellular_models_for_per_42ac6964_v1,
  title = {Patient Specific Cellular Models for Personalized Medicine},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/patient-specific-cellular-models-for-personalized-medicine/rdr_42ac6964bebe4580b691976098538141/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}